Abstract
Intravenous methotrexate (MTX) (10 mg), either alone or with oral aspirin (ASA) (3,900 mg/day), was administered to 15 patients with rheumatoid arthritis. Systemic and renal clearance of MTX were lower, and the unbound fraction of MTX was higher when patients were also receiving ASA than when taking MTX alone. No acute hematologic, renal, or hepatic toxicity was observed with either treatment. The findings of this study therefore indicate that concomitant aspirin therapy acutely alters the clearance of low-dose MTX in patients with rheumatoid arthritis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Adult
-
Arthritis, Rheumatoid / metabolism*
-
Aspirin / administration & dosage
-
Aspirin / pharmacology*
-
Blood Proteins / metabolism
-
Creatinine / blood
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Injections, Intravenous
-
Kidney / pathology
-
Male
-
Metabolic Clearance Rate / drug effects
-
Metabolic Clearance Rate / physiology
-
Methotrexate / blood
-
Methotrexate / pharmacokinetics*
-
Methotrexate / urine
-
Middle Aged
-
Protein Binding
Substances
-
Blood Proteins
-
Creatinine
-
Aspirin
-
Methotrexate